Vertex Pharmaceuticals Inc Market Cap ($130.90 Billion)
Market Cap & Net Worth: Vertex Pharmaceuticals Inc (VRTX)
Vertex Pharmaceuticals Inc market cap. Vertex Pharmaceuticals Inc (NASDAQ:VRTX) has a market capitalization of $130.90 Billion ($130.90 Billion) as of November 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #182 globally and #101 in its home market, demonstrating a 4.43% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Vertex Pharmaceuticals Inc's stock price $558.88 by its total outstanding shares 253460924 (253.46 Million). Also see cash flow conversion of Vertex Pharmaceuticals Inc for how efficiently the company converts equity into cash flow.
Vertex Pharmaceuticals Inc Market Cap History (2015–2026)
Vertex Pharmaceuticals Inc market cap history from 2015 to 2026. Data shows growth from $31.89 Billion to $141.65 Billion (15.32% CAGR). Check Vertex Pharmaceuticals Inc (VRTX) share price today for real-time trading data and today's change.
Index Memberships
Vertex Pharmaceuticals Inc is a constituent of 7 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Biotechnology
BTK
|
$1.06 Trillion | 12.40% | #3 of 30 |
|
Dow Jones Biotechnology
DJUSBT
|
$1.15 Trillion | 11.42% | #4 of 39 |
|
S&P 500 Index
GSPC
|
$61.47 Trillion | 0.27% | #82 of 503 |
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 5.01% | #5 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.33% | #37 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 7.12% | #4 of 263 |
|
Nasdaq 100
NDX
|
$33.67 Trillion | 0.39% | #34 of 101 |
Weight: Vertex Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Vertex Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Vertex Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of Vertex Pharmaceuticals Inc to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
9.52x
Vertex Pharmaceuticals Inc's market cap is 9.52 times its annual revenue
Latest Price to Earnings (P/E) Ratio
29.07x
Vertex Pharmaceuticals Inc's market cap is 29.07 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $18.67 Billion | $1.70 Billion | -$112.05 Million | 10.97x | N/A |
| 2017 | $37.98 Billion | $2.49 Billion | $263.48 Million | 15.26x | 144.16x |
| 2018 | $42.00 Billion | $3.05 Billion | $2.10 Billion | 13.78x | 20.03x |
| 2019 | $55.50 Billion | $4.16 Billion | $1.18 Billion | 13.33x | 47.16x |
| 2020 | $59.90 Billion | $6.21 Billion | $2.71 Billion | 9.65x | 22.09x |
| 2021 | $55.66 Billion | $7.57 Billion | $2.34 Billion | 7.35x | 23.77x |
| 2022 | $73.19 Billion | $8.93 Billion | $3.32 Billion | 8.20x | 22.03x |
| 2023 | $103.13 Billion | $9.87 Billion | $3.62 Billion | 10.45x | 28.49x |
| 2024 | $102.07 Billion | $11.02 Billion | -$535.60 Million | 9.26x | N/A |
| 2025 | $114.91 Billion | $12.07 Billion | $3.95 Billion | 9.52x | 29.07x |
Competitor Companies of VRTX by Market Capitalization
Companies near Vertex Pharmaceuticals Inc in the global market cap rankings as of November 1, 2026. Also see VRTX total assets for a full breakdown of the balance sheet.
Key companies related to Vertex Pharmaceuticals Inc by market ranking:
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
- Argen-X (BR:ARGX): Ranked #562 globally with a market cap of $47.46 Billion USD ( €40.60 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
| #562 | Argen-X | BR:ARGX | $47.46 Billion | €807.20 |
Market Capitalization of Vertex Pharmaceuticals Inc (2015–2026)
Market capitalization of Vertex Pharmaceuticals Inc from 2015 to today. Between 2015 and today, Vertex Pharmaceuticals Inc's market cap moved from $31.89 Billion to $ 141.65 Billion, with a yearly change of 15.32%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $141.65 Billion | +23.28% |
| 2025 | $114.91 Billion | +12.58% |
| 2024 | $102.07 Billion | -1.03% |
| 2023 | $103.13 Billion | +40.90% |
| 2022 | $73.19 Billion | +31.50% |
| 2021 | $55.66 Billion | -7.08% |
| 2020 | $59.90 Billion | +7.94% |
| 2019 | $55.50 Billion | +32.13% |
| 2018 | $42.00 Billion | +10.58% |
| 2017 | $37.98 Billion | +103.42% |
| 2016 | $18.67 Billion | -41.45% |
| 2015 | $31.89 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Vertex Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $130.90 Billion USD |
| MoneyControl | $130.90 Billion USD |
| MarketWatch | $130.90 Billion USD |
| marketcap.company | $130.90 Billion USD |
| Reuters | $130.90 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with C… Read more